Evidence map›Paper›PMID 31062234›Full record

Trial reportEndocrine2019

CRH stimulation improves

Jacqueline Boyle, Nicholas J Patronas, James Smirniotopoulos, Peter Herscovitch, William Dieckman, Corina Millo, Dragan Maric, Grégoire P Chatain, Christina Piper Hayes, Sarah Benzo and 9 more

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Endocrine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 2 pooled it
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 42 citations in OpenAlex.

  1. MRI for Cushing Disease: A Systematic Review.AJNR. American journal of neuroradiology · 2023
    Pooled it
  2. Pooled it
  3. Prospective Multicenter Evaluation of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025
    Trial
  4. Functional pituitary adenoma imaging.Reviews in endocrine & metabolic disorders · 2026
    Review
  5. Review
  6. [Frontiers in endocrinology · 2026
    Article
  7. Article
  8. Review
  9. Review
  10. Dexamethasone suppression forCancer imaging : the official publication of the International Cancer Imaging Society · 2023
    Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 11 institutions in 1 country.

Jacqueline BoyleNeurosurgery Unit for Pituitary and Inheritable Diseases, National Institute of Neurological Diseases and Stroke, Bethesda, MD, USA.
Nicholas J PatronasDiagnostic Radiology, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, MD, USA.
James SmirniotopoulosDepartment of Radiology, George Washington University, Washington, DC, USA.
Peter HerscovitchDepartment of Positron Emission Tomography, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, MD, USA.
William DieckmanDepartment of Positron Emission Tomography, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, MD, USA.
Corina MilloDepartment of Positron Emission Tomography, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, MD, USA.
Dragan MaricFlow Cytometry Core Facility, National Institute of Neurologic Diseases and Stroke, Bethesda, MD, USA.
Grégoire P ChatainSurgical Neurology Branch, National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA.
Christina Piper HayesDepartment of Neurosurgery, University of Colorado, Denver, CO, USA.
Sarah BenzoDepartment of Neurosurgery, University of Colorado, Denver, CO, USA.
Gretchen ScottDepartment of Neurosurgery, University of Colorado, Denver, CO, USA.
Nancy EdwardsDepartment of Neurosurgery, University of Colorado, Denver, CO, USA.
Abhik Ray ChaudhuryDepartment of Neurosurgery, University of Colorado, Denver, CO, USA.
Maya B LodishSection on Endocrinology and Genetics, Pediatric Endocrinology Inter-Institute Training Program, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD, USA.
Susmeeta SharmaPituitary Endocrinology Section, MedStar Washington Hospital Center, Washington, DC, USA.
Lynnette K NiemanDiabetes, Endocrinology and Obesity Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA.
Constantine A StratakisSection on Endocrinology and Genetics, Pediatric Endocrinology Inter-Institute Training Program, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD, USA.
Russell R LonserDepartment of Neurological Surgery, The Ohio State University, Columbus, OH, USA.
Prashant ChittiboinaNeurosurgery Unit for Pituitary and Inheritable Diseases, National Institute of Neurological Diseases and Stroke, Bethesda, MD, USA. prashant.chittiboina@nih.gov.
University of Colorado Denver · USEunice Kennedy Shriver National Institute of Child Health and Human Development · USItron (United States) · USNational Institute of Neurological Disorders and Stroke · USGeorge Washington University · USIllinois College · USMedStar Washington Hospital Center · USNational Institute of Diabetes and Digestive and Kidney Diseases · USNational Institutes of Health · USNational Institutes of Health Clinical Center · USNeurological Surgery · US

Funding

Molecular Genetics of Endocrine Tumors and Related DisordersZIAHD008920 · NICHD · EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT · PI STRATAKIS, CONSTANTINE A. · 2012 to 2021
$25.8M
Improved Diagnosis and Treatment of Cushing's DiseaseZIANS003150 · NINDS · NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE · PI CHITTIBOINA, PRASHANT · 2015 to 2025
$13.7M
NIH HHS NS003150-01
6 · The paper itself

Abstract

objectiveIn MRI-negative cases Cushing's disease (CD), surgeons perform a more extensive exploration of the pituitary gland, with fewer instances of hormonal remission.

methodsSubjects with a likely diagnosis of CD (n = 27, 20 females) each underwent two

resultsThe mean-SUV of adenomas was significantly increased from baseline (3.6 ± 1.5) with oCRH administration (3.9 ± 1.7; one-tailed p = 0.003). Neuroradiologists agreed that adenomas were visible on 21 scans, not visible on 26 scans (disagreed about 7, kappa = 0.7). oCRH-stimulation led to the detection of additional adenomas (n = 6) not visible on baseline-PET study. Of the MRI-negative adenomas (n = 5), two were detected on PET imaging (one only after oCRH-stimulation). USP8 mutations or glycolytic pathway proteins were not associated with SUV in corticotropinomas.

conclusionsThe results of the current study suggest that oCRH-stimulation may lead to increased CLINICAL TRIAL INFORMATION:

Indexed as

Fluorodeoxyglucose F18ACTH-Secreting Pituitary AdenomaAdenomaAdolescentAdultChildCorticotropin-Releasing HormoneDiagnosis, DifferentialFemaleHumansMaleMiddle AgedPituitary ACTH HypersecretionPositron-Emission TomographySensitivity and SpecificityYoung AdultCorticotropin-Releasing HormoneFluorodeoxyglucose F18CRHCushing’s diseasePET imagingPituitary adenomaSecretagogueTranssphenoidal surgery

Identifiers

PMID31062234
OpenAlexW2944472407

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.